Health Care·Life Sciences Tools & Services·$32.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.77 | N/A | +14.75% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.77 | N/A | +14.75% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's direction despite not providing specific guidance. They noted positive trends in demand and operational improvements.
Management highlighted strong performance in key segments.
They emphasized ongoing investments in innovation.
There was a focus on maintaining operational efficiency.
Agilent Technologies reported better-than-expected earnings per share, which contributed to a 2.16% increase in stock price. The positive surprise in EPS reflects the company's ability to manage costs effectively and perform well in its market segments. However, the lack of revenue data and future guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SUPERNUS PHARMACEUTI
May 13, 2013